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Abstract: Vascular smooth muscle cells (VSMCs) are central players in carotid atherosclerosis
plaque development. Although the precise mechanisms involved in plaque destabilization are
not completely understood, it is known that VSMC proliferation and migration participate in
plaque stabilization. In this study, we analyzed expression patterns of genes involved in carotid
atherosclerosis development (e.g., transcription factors of regulation of SMC genes) of VSMCs located
inside or outside the plaque lesion that may give clues about changes in phenotypic plasticity
during atherosclerosis. VSMCs were isolated from 39 carotid plaques extracted from symptomatic
and asymptomatic patients by endarterectomy. Specific biomarker expression, related with VSMC
phenotype, was analyzed by qPCR, western immunoblot, and confocal microscopy. MYH11, CNN1,
SRF, MKL2, and CALD1 were significantly underexpressed in VSMCs from plaques compared
with VSMCs from a macroscopically intact (MIT) region, while SPP1, KLF4, MAPLC3B, CD68, and
LGALS3 were found significantly upregulated in plaque VSMCs versus MIT VSMCs. The gene
expression pattern of arterial VSMCs from a healthy donor treated with 7-ketocholesterol showed
high similarity with the expression pattern of carotid plaque VSMCs. Our results indicate that VSMCs
isolated from plaque show a typical SMC dedifferentiated phenotype with macrophage-like features
compared with VSMCs isolated from a MIT region of the carotid artery. Additionally, MYH11,
KLF5, and SPP1 expression patterns were found to be associated with symptomatology of human
carotid atherosclerosis.
Keywords: carotid atherosclerosis; plaque instability; smooth muscle cells; MYH11
1. Introduction
Carotid atherosclerosis is a chronic progressive vascular disease which can lead to symptoms
such as stroke [1]. Unstable carotid atheroma plaques are those that can rupture causing an ischemic
attack [2,3], however, the precise mechanisms underlying plaque destabilization and consequent
rupture remain unclear [4]. Vascular smooth muscle cell (VSMC) dedifferentiation is known to play
a role in atherosclerosis development [5]. VSMCs found in healthy arteries represent a mature, fully
differentiated stage and express the factors needed to ensure their specific contractile features [6].
These cells also display high plasticity capacity compared with other muscle cell types [7]. In the
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context of atherosclerosis, VSMCs are believed to dedifferentiate, proliferate, and migrate, thus
contributing to plaque formation [5]; however, VSMCs may also display beneficial roles by protecting
against plaque rupture through promotion of plaque repair [8–11]. Therefore, VSMCs play an
essential role during plaque development from moderate stage to advanced atheroma plaques [12–14].
This process of cellular physiology change is called “switching of VSMCs” and indicates a change
in their phenotype from differentiated contractile-state to dedifferentiated synthetic-state, which is
considered a pre-requisite for the first stages of plaque development [5]. The characteristics of these
two phenotypes, contractile and synthetic, represent the two opposite ends of the spectrum of VSMCs
among which VSMCs with intermediate phenotypes are found [15]. In response to distinct signals,
VSMCs can switch in either direction, synthetic- or contractile-state; thus, proliferative VSMCs could
reacquire some contractile VSMC characteristics when suitable surrounding signals are present [6].
Recently, Shankman et al. [16] reported that the effects of VSMCs during atherosclerosis may be
dependent on the phenotypic modulation features. A recent proteomics study disclosed a number
of proteins differentially expressed during VSMC phenotypic modulation and, interestingly, most of
these are involved in cell migration and adhesion [17]. During phenotypic modulation, VSMCs
decrease expression of specific markers of the contractile phenotype and increase those of the synthetic
phenotype [6,18]. Thus, changes in contractile proteins such as myosin heavy chain 11 (MYH11)
and its relationship to cytoskeletal components have been associated with the phenotype switch of
VMSCs [19].
The recognition of the synthetic phenotype mostly relies upon the reduced expression or the
absence of cytoskeletal markers of the mature or differentiated phenotype [7,20]. Thereby, the rigorous
identification of mature SMCs requires examination of multiple marker genes [6,21]. Although
atherosclerosis has been intensively studied in humans, the exact involvement of VSMCs in plaque
rupture remains unclear. Current literature tends to be more focused on understanding the role of
VSMCs coming from the coronary rather than carotid artery. However, a recent study has demonstrated
that the biology of atherosclerosis in these two arterial beds is different, and thus the involvement of
VSMCs too. For instance, vulnerable carotid plaques have a thicker fibrous cap and higher prevalence
of calcified nodules than coronary plaques, two characteristics in which VSMCs have a role, and
that may modulate plaque rupture [22,23]. Due to these differences in the behavior of VSMCs, there
is a need of deep knowledge on the role of VSMCs in human carotid atherosclerotic plaques and
especially of their involvement in plaque rupture and consequent symptoms. In this study, we have
characterized VSMCs from human carotid atheroma plaques through analyzing specific markers for
contractile, synthetic, and foam cell/macrophage-like cell phenotypes in two different areas of the
plaque; the center of the lesion (PLQ) and the furthest site from the lesion (macroscopically intact
tissue, MIT) within the surgically excised carotid area. Moreover, the obtained results of VSMC
phenotypes have been correlated with patient symptomatology, with the aim to gain comprehension
about the role of VSMCs in plaque destabilization.
2. Materials and Methods
2.1. Isolation of Human Vascular Smooth Muscle Cells
Carotid endarterectomy (CEA) surgery was carried out at Basurto University Hospital
(Bilbao, Spain) in 39 patients of carotid atherosclerosis disease. CEA was performed in symptomatic
patients (n = 20) who presented a degree of stenosis higher than 70% with previous history of
transient ischemic attack or ipsilateral stroke, and in asymptomatic patients (n = 19) with a degree
of stenosis higher than 80% and no cerebrovascular associated symptoms. All patients underwent
an MRI scan and cervical duplex before and after surgery. Demographic and clinical data for these
patients are summarized in Table 1. Carotid atheroma plaque samples were placed on ice and
processed immediately. VSMCs were extracted from tissue from the plaque site area (PLQ-SMCs)
and tissue from the furthest neighboring area from the lesion (MIT-SMCs), for each plaque sample
Cells 2018, 7, 23 3 of 14
obtained. Figure 1 shows two representative examples of affected and MIT areas used in this study.
An enzymatic tissue digestion method was used to isolate and culture VSMCs in two consecutive
digestions. First, tissue was digested by 3 h incubation at 5% CO2 and 37 ◦C with 300 U/mL of
Collagenase type I (ColI) (17018029, Thermo Fisher Scientific, Waltham, MA, USA) followed by a
second digestion over night with 220 U/mL of ColI at 5% CO2 and 37 ◦C. Digested tissue was filtered
by a 100 µm nylon Falcon™ Cell Strainer (CLS431752-50EA, Sigma-Aldrich, St. Louis, MO, USA) to
remove undigested tissue and subsequently cells were plated in T25 flasks with 5 mL of selective
medium, which consists of 231 medium (M231500, Thermo Fisher Scientific, Waltham, MA, USA) that
promotes selective VSMC growth, supplemented with 2 ng/mL FGFb (130-093-839, Miltenyi Biotec,
Bergisch Gladbach, Germany), 20 ng/mL IGF-1 (130-093-885, Miltenyi Biotec, Bergisch Gladbach,
Germany), 0.5 ng/mL EGF (130-0997-749 Miltenyi Biotec, Bergisch Gladbach, Germany), 5 ng/mL
Heparin (H3149, Sigma-Aldrich, St. Louis, MO, USA), 5% newborn calf serum (N4762, Sigma-Aldrich,
St. Louis, MO, USA), 0.2 µg/mL bovine serum albumin (BSA) (A9418, Sigma-Aldrich, St. Louis, MO,
USA), 2 mM L-glutamine (G7513, Sigma-Aldrich, St. Louis, MO, USA), 100 µg/mL Streptomycin, and
100 U/mL Penicillin (P4458, Sigma-Aldrich, St. Louis, MO, USA). Cell density at harvest was 200,000
cells/5 mL in a T25 flask. All experiments were carried out with cells in passage zero in order to keep
overall cell characteristics as similar as possible to those in the natural context, and to avoid extended
cultivation periods which would influence the expression levels of analyzed genes [14].
Table 1. Demographic and clinical data from asymptomatic and symptomatic patients. Statistical
analysis was performed with the chi-square test for all parameters except age, for which the
non-parametric Mann–Whitney U test was used. p-value ≤ 0.05 was considered significant.
Patient Characteristics Asymptomatic Symptomatic p-Value
n 19 20
Age 68 ± 9 71 ± 8 ns (0.5)
Sex 14 male/5 female 16 male/4 female ns (0.6)
Risk Factors (%)
Contralateral occlusion 66 61 ns (1.0)
Hypertension 66 69 ns (1.0)
Diabetes mellitus 51 8 ns (0.09)
Augmented cholesterol 83 62 ns (0.3)
Cardiopathy 0 23 ns (0.2)
Ischemic cardiopathy 41 46 ns (1.0)
Atrial fibrillation 9 23 ns (0.6)
Intermittent claudication 26 24 ns (1.0)
Tobacco 16 8 ns (0.6)
Medications (%)
Statins 100 70 ns (0.1)
Anticoagulant 8 23 ns (0.2)
This study was approved by the local ethical committee (Ethical committee of clinical research,
Basurto University Hospital) and all carotid atheroma plaques were collected from patients who had
signed written informed consent. This research was performed in agreement with the principles
outlined in the Declaration of Helsinki.
Human iliac arterial smooth muscle cells were obtained from the Coriell Cell Repositories
(Coriell AG11545, Camden, NJ, USA). These cells were obtained by explant method of iliac arterial
tissue. The culture was grown on flasks coated with 0.1% gelatin (G8090, Sigma-Aldrich, St. Louis,
MO, USA) and 199 medium (11150059, Thermo Fisher Scientific, Waltham, MA, USA) supplemented
with 0.02 mg/mL ECGS (02-102, Millipore, Billerica, MA, USA) and 0.05 mg/mL heparin (H3149,
Sigma-Aldrich, St. Louis, MO, USA), 10% fetal bovine serum (FBS) (F7524, Sigma-Aldrich, St. Louis,
MO, USA), 2 mM L-glutamin (G7513, Sigma-Aldrich, St. Louis, MO, USA), 100 µg/mL Streptomycin
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and 100 U/mL Penicillin (P4458, Sigma-Aldrich, St. Louis, MO, USA) in T25 flasks. Cell density at
harvest was 200.000 cells/5 mL in a T25 flask.
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used were anti-alpha smooth muscle actin at 1/100 (ab66133, Abcam, Cambridge, UK), 
transgelin/SM22 monoclonal antibody at 1/100 (60213-1-Ig, ProteinTech, Manchester, UK) and anti-
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RNA was extracted from VSMCs with PureLink® RNA mini kit (12183018A, Thermo Fisher 
Scientific, Waltham, MA, USA) followed by DNaseI treatment (12185010, Thermo Fisher Scientific, 
Waltham, MA, USA). RNA was retrotranscribed with High-Capacity cDNA Reverse Transcription 
Kit (4368814, Applied Biosystems™, Thermo Fisher Scientific, Waltham, MA, USA) using 160 ng of 
RNA. Gene expression analysis was carried out using Fast SYBR® Green Master Mix (4385614, 
Thermo Fisher Scientific, Waltham, MA, USA) in ABI7500Fast Real-Time PCR instrument (Applied 
Biosystems™, Carlsbad, CA, USA). Primers for genes related with contractile phenotype were α-
smooth muscle actin (ACTA2), MYH11, h-caldesmon (CALD1), calponin 1 (CNN1), and transgelin 
(TAGLN); for synthetic phenotype were myosin heavy chain 10 (MYH10), intercellular adhesion 
molecule 1 (ICAM1), secreted phosphoprotein 1 (SPP1, also osteopontin), matrix metallopeptidase 
(MMP) 3, 7, 9, tissue inhibitor of metallopeptidase 1 (TIMP1), and microtubule associated protein 1 
light chain 3 beta (MAP1LC3B); primers for transcription factors related with specific SMCs 
differentiation were MKL1/Myocardin like 2 (MKL2), serum response factor (SRF), kruppel like factor 
Figure 1. Illustrative photos of carotid endarterectomy specimens. Macroscopically intact tissue and
atherosclerotic tissue is visualized on sample from patient 1 (A) and patient 2 (B).
2.2. Flow Cytometry
VSMC cultures were trypsinized at cell density of 200,000 cells/5 mL in T25 flasks and then fixed
with 4% paraformaldehyde during 10 min at room temperature. VSMCs were permeabilized with
0.5% saponin (S7900, Sigma-Aldrich, St. Louis, MO, USA) in phosphate-buffered saline (PBS) for
5 min and blocked with 1% BSA (A6003, Sigma-Aldrich, St. Louis, MO, USA) for 30 min. Primary
antibodies used were anti-alpha smooth muscle actin at 1/100 (ab66133, Abcam, Cambridge, UK),
transgelin/SM22 monoclonal antibody at 1/100 (60213-1-Ig, ProteinTech, Manchester, UK) and
anti-CD31 (also called platelet and endothelial cell adhesion molecule 1, PECAM1) [EPR3094] antibody
at 1/50 (ab76533, Abcam, Cambridge, UK) during 1 h in shaking at room temperature. VSMCs were
washed with 5 mM EDTA (E7889, Sigma-Aldrich, St. Louis, MO, USA) and 0.5% BSA in PBS and
were incubated with secondary antibodies Alexa Fluor® 488 goat anti-mouse IgG (H + L) (A-11001,
Invitrogen, Thermofisher, Carlsbad, CA, USA) and Alex Fluor® 647 goat anti-rabbit IgG (H + L)
(A-21244, Invitrogen, Thermofisher, Carlsbad, CA, USA) at 1/500 for 30 min in shaking and darkness.
After washing, cells were resuspended in 5 mM EDTA and 0.5% BSA in PBS.
2.3. Gene Expression Analysis
RNA was extracted from VSMCs with PureLink® RNA mini kit (12183018A, Thermo Fisher
Scientific, Waltham, MA, USA) followed by DNaseI treatment (12185010, Thermo Fisher Scientific,
Waltham, MA, USA). RNA was retrotranscribed with High-Capacity cDNA Reverse Transcription Kit
(4368814, Applied Biosystems™, Thermo Fisher Scientific, Waltham, MA, USA) using 160 ng of RNA.
Gene expression analysis was carried out using Fast SYBR® Green Master Mix (4385614, Thermo Fisher
Scientific, Waltham, MA, USA) in ABI7500Fast Real-Time PCR instrument (Applied Biosystems™,
Carlsbad, CA, USA). Primers for genes related with contractile phenotype were α-smooth muscle actin
(ACTA2), MYH11, h-caldesmon (CALD1), calponin 1 (CNN1), and transgelin (TAGLN); for synthetic
phenotype were myosin heavy chain 10 (MYH10), intercellular adhesion molecule 1 (ICAM1), secreted
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phosphoprotein 1 (SPP1, also osteopontin), matrix metallopeptidase (MMP) 3, 7, 9, tissue inhibitor
of metallopeptidase 1 (TIMP1), and microtubule associated protein 1 light chain 3 beta (MAP1LC3B);
primers for transcription factors related with specific SMCs differentiation were MKL1/Myocardin
like 2 (MKL2), serum response factor (SRF), kruppel like factor (KLF) 4 and 5; primers for genes related
with macrophage-like phenotype were CD68 molecule (CD68) and galectin 3 (LGALS3) (Table S1).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ribosomal protein 41 (RPL41) and β-actin
(ACTB) were tested as housekeeping genes. The geometric mean of GAPDH and RPL41 was used
for data analysis due to their stable gene expression values across samples [24]. PCR amplification
efficiencies were in all cases close to 100%. Results were analyzed using ∆Ct method. We analyzed gene
expression by taking into account the localization of VSMCs, PLQ-VSMCs (n = 39), or MIT-VSMCs
(n = 39) using the Wilcoxon matched-pairs signed rank test. The Mann–Whitney U test was used to
analyze gene expression patterns between plaque VSMCs from asymptomatic (n = 20) and symptomatic
(n = 19) patients, as well as the expression levels of 15 µM 7-ketocholesterol-treated HIASMCs versus
not-treated HIASMCs (3 independent experiments). Statistical analysis was performed with GraphPad
Prism 5 software. p value < 0.05 was considered significant.
2.4. Western Blot
Protein extraction was carried out with RIPA lysis buffer (150 mM TrisHCL, 150 mM NaCl, 0.5%
Deoxycholate, 0.1% SDS, 1% NP-40) for 30 min at 4 ◦C followed by centrifugation at 20,000× g for
10 min in trypsinized VSMCs. Cell lysates were quantified by Pierce™ BCA Protein Assay Kit (23225,
Thermo Fisher Scientific, Waltham, MA, USA) and 12 µg protein were loaded into 6% or 12% SDS-PAGE
gels with reducing loading buffer. Then, proteins were transferred from SDS-PAGE gel to 0.45 µm-pore
PVDF membrane. PVDF membranes were blocked with 2% casein solution following incubation
with primary antibody anti-smooth muscle Myosin heavy chain 11 (ab82541, Abcam, Cambridge, UK)
and then washed with TBS-Tween. The secondary antibody was anti-rabbit horseradish peroxidase
conjugate (#7074, Cell Signaling Technology, MA, USA) and as housekeeping anti-GAPDH antibody
(MAB374, Millipore, Billerica, MA, USA) was used for normalization. Proteins were detected with
Immobilon™ Western Chemiluminescence HRP Substrate detection reagent (WBKLS0500, Millipore,
Billerica, MA, USA) and were visualized with the ChemiDoc™ XRS Imaging System (Bio-Rad, Hercules,
CA, USA). Data analysis was done by densitometry comparing MIT (n = 7) and PLQ (n = 7) cells
and additionally, between A (n = 6) and S (n = 5) plaque VSMCs, both using Image Lab™ Software
(Bio-Rad, Hercules, CA, USA).
2.5. Confocal Microscopy
Cells were grown on round 14 mm glass coverslips (Thermo Scientific, Waltham, MA, USA), fixed
in ice-cold methanol for 10 min at room temperature and then blocked in PBS/3% w/v BSA (A6003,
Sigma-Aldrich, St. Louis, MO, USA) for 30 min and stained with primary antibody anti-smooth muscle
Myosin heavy chain 11 (ab82541, Abcam, Cambridge, UK) for 1 h at room temperature. Cells were
washed in PBS pH 7.45 and incubated with Alexa Fluor® 488 goat anti-rabbit IgG (H + L) (A-11008,
Invitrogen, Thermofisher, Carlsbad, CA, USA) secondary antibody for 45 min at room temperature
in darkness and DNA was counterstained with 4′,6-diamino-2-fenilindol (DAPI). After three washes,
coverslips were mounted in Fluoromount™ Aqueous Mounting Medium (F4680, Sigma-Aldrich,
St. Louis, MO, USA). Image acquisition was performed with Leica TCS STED CW SP8 Super-Resolution
Microscope with a 40× lens and recording optical sections every 0.3 µm. Image analysis was done
analyzing MYH11 staining fluorescence of each cell per cell area in MIT and PLQ VSMCs with ImageJ
software (National Institute of Health, Bethesda, MD, USA).
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3. Results
3.1. VSMC Isolation from Human Carotid Atheroma Plaque
Human carotid atherosclerotic plaque tissues obtained by carotid endarterectomy surgery were
enzymatically digested and once cells were totally disaggregated from tissue, we routinely analyzed the
presence of two specific markers of VSMCs i.e., ACTA2 and TAGLN, together with that of endothelial
cell marker PECAM1 by flow cytometry in 39 PLQ-VSMCs and 39 MIT-VSMCs. VSMC suspension
was 90% ACTA2+ and almost 100% of VSMCs isolated from carotid tissue were TAGLN+, whereas
endothelial cell marker PECAM-1 was nearly absent with just 2% of cells expressing it, together
indicative for VSMCs cultures devoid of endothelial cells following cultivation in VSMC-selective
culture medium. Figure 2 shows an illustration of flow cytometry detection of those markers in one
representative cell culture.
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Human iliac arterial smooth muscle cells (HIASMCs) from a healthy donor treated with
7-ketocholesterol (7-KC) were used to mimic the physiological environment to which SMCs are
exposed during atherosclerosis development. HIASMCs showed also a marked decrease of contractile
biomarkers when treated during 24 h with 15 µM 7-ketocholesterol (Figure 3B), an oxysterol which is
abundant in the plaque.
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Figure 3. (A) Fold change differences of contractile and synthetic marker expression in 39 plaque
VSMCs (PLQ-VSMCs) versus 39 macroscopically intact tissue area VSMCs (MIT-VSMCs) analyzed by
quantitative PCR (error bars represent ± SEM n = 39). Data was normalized with GAPDH and
RPL41. Wilcoxon matched-pairs signed rank test (p < 0.05 * and p < 0.01 **); (B) Fold change
differences of contractile and synthetic marker expression in 7-ketocholesterol treated (15 µM)
HIASMCs versus not treated human iliac arterial SMCs (HIASMCs) analyzed by quantitative PCR
(error bars represent ± SEM n = 3). Non-parametric Mann–Whitney U test was used (p < 0.05 *).
Transcriptional regulatory pathways control the expression of VSMCs markers and are governed
by the transcription factors SRF, MKL2, KLF4, and KLF5. SRF and MKL2 were both downregulated in
PLQ-VSMCs (Figure 3A). KLF4, which has been reported to suppress expression of SMCs markers,
at least in part by disrupting SRF–myocardin interaction, showed higher levels of expression in
PLQ-VSMCs [16]. On the other hand, KLF5 expression did not differ significantly between PLQ-VSMCs
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and MIT-VSMCS (Figure 3A). HIAVSMCs treated with 7-KC showed a similar pattern of transcription
factor expression levels as VSMC isolated from carotid plaques (Figure 3B) with SRF diminished and
KLF4 enhanced upon 7-KC treatment.
In a recent study, VSMCs isolated from carotid atherosclerotic plaques were found to express a
series of macrophage markers [14], concomitant with a macrophage-like phenotype [25]. Analysis of
the expression levels of CD68 and LGALS3 showed that both macrophage markers were significantly
augmented in PLQ compared to MIT-VSMCs (Figure 3A). Similarly, when HIASMCs were treated with
7KC, both genes were clearly upregulated (Figure 3B). Thus, VSMCs in the lesion have been driven
towards a phenotype with partial characteristics of macrophages.
To verify that these differences were not due to symptomatology, we analyzed the gene expression
data separately using either only symptomatic samples (20 PLQ-VSMCS vs. 20 MIT-VSMCs) (Figure S1A)
or only asymptomatic samples (19 PLQ-VSMCS vs. 19 MIT-VSMCs) (Figure S1B). As similar patterns
of expression were observed in both cases, the differences in gene expression found (Figure 3A) are
independent of symptomatology and due to the location within the excised carotid area.
3.3. MYH1, SPP1, and KLF5 Emerge as Differentially Expressed Genes between Symptomatic and
Asymptomatic Carotid VSMC
The gene expression pattern in atheroma PLQ-VSMCs isolated from symptomatic and asymptomatic
patients was also analyzed. We found MYH11 and KLF5 to be significantly underexpressed in VSMCs
from symptomatic patients compared with those from asymptomatic patients (p = 0.045 and p = 0.01
respectively, Table 2), while SPP1 was upregulated (p = 0.05).
Table 2. Relative gene expression analysis between 20 symptomatic (SYMPT) VSMCs and
19 asymptomatic (ASYMPT). Gene expression was normalized with the housekeeping genes GAPDH and
RPL41. Differences between the two groups were analyzed with Mann–Whitney U Test. p-value ≤ 0.05
was considered significant. (FC, fold change).
Gene Symbol FC (Asympt vs. Sympt) p Value
Actin, alpha 2, smooth muscle, aorta (ACTA2) 1.3 ns
CD68 molecule (CD68) −1.01 ns
Caldesmon 1 (CALD1) −1.17 ns
Calponin 1 (CNN1) 1.14 ns
Galectin 3 (LGALS3) 1.05 ns
Intercellular adhesion molecule 1 (ICAM1) −1.30 ns
Kruppel like factor 4( KLF4) 1.04 ns
Kruppel like factor 5 (KLF5) −1.89 0.01
Microtubule associated protein 1 light chain 3 beta −1.09 ns
MKL1/myocardin like 2 (MKL2) −1.17 ns
Myosin heavy chain 10 (MYH10) −1.31 ns
Myosin heavy chain 11 (MYH11) −4.53 0.045
Secreted phosphoprotein 1 (SPP1) 2.08 0.05
Serum response factor (SRF) −1.38 ns
Transgelin (TAGLN) −1.01 ns
3.4. MYH11 Expression in VSMCs from Symptomatic vs. Asymptomatic Patients and from PLQ vs.
MIT Region
In immunoblot analysis, MYH11 levels were underexpressed both in PLQ-VSMCs compared with
MIT-VSMCs (Figure 4A, panels a and b) and in VSMCs coming from symptomatic versus asymptomatic
patients (Figure 4A, panels c and d).
Immunocytofluorescence analysis with anti-MYH11 by confocal microscopy was performed in
carotid VSMCs with the aim to describe the contractile system. PLQ-VSMCs and MIT-VSMCs were
labeled with anti-MYH11 and DAPI to identify nuclei. Individual myofilaments were not found to be
parallel to the long axis of the cell but formed a network of filaments, and they appeared distributed in
Cells 2018, 7, 23 9 of 14
the cytoplasm in all single planes of the Z-stacks images, from the base (at the cover slip) to the top
of the cell. Z-stack images showed homogeneous distribution of myosin filaments creating a thick
fiber-mesh in the base of the cell; myosin-containing stress fibers extended as a network towards the
periphery of the cell (Figure 4B, panel a), whereas fibers usually end in extending lamellae, and MYH11
appeared as continuous spots (Figure 4B, panel b) [26]. In the upper planes of Z-stacks there was
predominant staining of MYH11 in the central region of the cytoplasm with weaker staining in the cell
periphery, which could be observed in MIT-VSMCs (Figure S2, upper panels), whereas there was lack
of this pattern in PLQ-VSMCs cells (Figure S2 lower panels). Additionally, in this study, we found
that MIT cells showed a higher volume of myofilaments per cell area (Figure 4B, panels c and d) than
those VSMCs from the center of atheroma plaque (Figure 4B, panel e), which exhibit less fluorescence
intensity of myosin staining.
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Figure 4. (A) MYH11 protein expression in carotid atherosclerotic VSMCs. (a,b) Western Blot of MYH11
protein in plaque or adjacent MIT area VSMCs, and asymptomatic or symptomatic plaque VSMCs,
respectively; (c,d) graphic representation of A and B show the average of densitometry values of the
bands respect to GAPDH protein expression. (MIT: macroscopically intact tissue area VSMCs; PLQ:
plaque VSMCs; ASYMPT: VSMCs from asymptomatic plaques; SYMPT: VSMCs from symptomatic
plaques) (p < 0.05 * and p < 0.01 ** were considered statistically significant); (B) Immunofluorescence
of carotid atherosclerotic VSMCs with MYH11 and nuclei staining. (a) MIT-VSMC myofilaments
extend throughout the cell forming a network with weaker MYH11 staining in the cell periphery;
(b) with 2.00 zoom focusing on the cell periphery where MYH11 staining a p ars as spots; (c,d) show
MYH11 staining in MIT-VSMCs (c image shows elongated and spindle-shaped c ll; and , flattened
and polarized cell with lamellipodia); (e) PLQ-VSMCs present low fluorescence intensity of MYH11
protein and appear forming thin myofilaments. Scale bar 50 µm.
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3.5. MMP3, MMP7, MMP9, and TIMP1 Do Not Emerge as Differentially Expressed in VSMCs Coming from
Asymptomatic and Symptomatic Patients or between PLQ and MIT Area
The balance between the matrix accumulation and degradation determines plaque stability.
We analyzed metalloproteinase 3, 7, 9 and metalloproteinase inhibitor 1 expression levels in our VSMC
samples (symptomatic/asymptomatic and PLQ/MIT) (Figure S3A,B). No significant association was
found between expression levels of MMP3, MMP9, MMP7, and TIMP1 and phenotype of VSMCs
(symptomatic vs. asymptomatic samples, or PLQ vs. MIT regions).
4. Discussion
This study has documented the expression patterns of relevant genes associated with phenotypic
modulation in VSMCs by comparing carotid atherosclerotic lesions with macroscopically intact regions
located within the surgically excised carotid artery areas. In addition, the VSMCs’ expression pattern
was compared between those from symptomatic versus asymptomatic to evaluate if any changes were
associated with symptomatology or plaque rupture.
VSCMs express MKL2, which is a transcriptional co-factor for SMC-specific genes [27]. Myocardin
binds to the globally expressed transcription factor SRF, and this complex regulates the expression
of SMC-specific markers. SMC contractile specific genes contain a functional CArG box in their
promoter region, to which the myocardin–SRF complex binds in order to promote SMC gene expression.
The expression of transcription factors SRF and MKL2 was decreased in PLQ-VSMCs compared to
MIT-VSMCs. This result suggests that cells present in damaged areas have gone through a phenotypic
modulation possibly regulated by the SRF transcriptional pathway [16].
Furthermore, KLF-4 is a member of a large family of zinc finger-containing DNA-binding
transcription factors and is known to regulate the expression of SMC markers [28] since it is a repressor
of SRF/myocardin [29]. Krüppel-like factors have been identified as atheroprotective factors [30] and
KFL4, specifically, has been identified as a critical marker that regulates SMC phenotypic transition
inhibiting expression of contractile genes. Contrary to this, it has also been suggested to play a
pro-atherogenic role due to its involvement in inhibiting the cell proliferation cycle. KFL4 expression
is very low under basal conditions; however, injury promotes its expression in vascular tissues [31].
This evidence supports our observation that KLF-4 is upregulated in PLQ-VSMCs, suggesting that
de-differentiated VSMCs are mainly restricted to the area of the lesion, while MIT-VSMCs seem to
remain predominantly contractile.
VSMCs keep their plasticity and can undergo cellular modulation from contractile to
synthetic-state or reverse the phenotype toward the contractile stage in response to changes in local
environmental cues [32]. Upon injury in atherosclerosis, when remodeling is required, VSMCs are
able to switch between distinct phenotypes with a trend towards increased rates of proliferation and
migration accompanied by enhanced extracellular matrix component production. Also, calcification
or release of inflammatory signals is coordinated with a decrease in VSMC contractile markers [6].
The contractile function of VMSCs is achieved by expression of a unique repertoire of proteins such as
ACTA2, MYH11, CALD1, and SM22α/TAGLN [7]. We demonstrate here that carotid PLQ-VSMCs
showed a decreased expression of specific contractile phenotype markers MYH11 (protein and
mRNA level) and CALD1 (mRNA level) compared to MIT-VSMCs. MYH11 has been identified
as a marker for specific SMC lineage [6,33] and is a late marker during development, expressed only in
fully differentiated cells and showing a high degree of specificity for contractile phenotype VSMCs [34].
In addition, data obtained from HIASMCs from a healthy donor treated with 7KC, one of the major
components of oxidized lipoproteins in atheroma plaques, indicates that healthy VSMCs under these
conditions proceed towards a de-differentiation process. Furthermore, decreased levels of VSMC
contractile markers have been reported before in atherosclerosis [6]. Thus, our results suggest that
PLQ-VSMCs might have a decreased contractile capacity.
The process of VSMC phenotypic modulation is associated not only with changes in expression
levels of contractile proteins but also with the reorganization of these proteins within the cells [9].
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In our study, we found VSMCs from PLQ and MIT to be positive for MYH11 protein staining by
immunofluorescence microscopy and that PLQ-VSMCs showed a lower volume of myofilaments
per cell area with lower fluorescence intensity of the protein, in line with the results of a previous
work in which significantly reduced MYH11 protein staining was observed in switched VSMCs
coming from atherosclerotic carotids [19]. In addition, Song and coworkers [35] suggested that
myofilament disassembly, especially in the upper cortex, could reflect SMC phenotypic modulation,
contractile components degradation, and reorganization of contractile and cytoskeletal proteins within
the cell [36]. Similarly, our analysis performed by z-stack to observe the whole thickness of cells
showed that staining of MYH11 was predominant in the central region of the cytoplasm in the upper
planes of the MIT-VSMCs, unlike PLQ-VSMCs that displayed less prominent myosin staining in the
perinuclear area, in which myofilaments appeared to be disassembled, such Saltis et al. [37] reported
before. Therefore, immunofluorescence microscopy shows that MYH11 in MIT-VSMCs forms strong
myofilament bundles, whereas they appear as thin and disassembled fibers in PLQ-SMCs, which is
characteristic of phenotype modulation in VSMCs.
We have also found increased levels of CD68, LGALS3, and SPP1, together with the reduced
expression of contractile proteins in PLQ-VSMCs compared to VSMCs from MIT area, suggesting that
PLQ-VSMCs may have undergone a phenotypic alteration towards a macrophage-like cell to adapt to
such changes. This is consistent with results reported before [38,39], demonstrating that VSMCs have
the potential to become macrophage-like cells with a capacity to migrate and to display phagocytic
behavior to digest excessive material present at the lesion site. In line with this notion, we have also
analyzed the expression of the autophagy marker MAP1LC3B, which is known to be important in
the de-differentiation of VSMCs through removing contractile proteins by autophagy [40] and in
carotid plaque stability [41]. Interestingly, PLQ-VSMCs showed higher expression of MAP1LC3B than
MIT-VSMCs. HIASMCs treated with 7KC also exhibited increased autophagy marker MAP1LC3B
expression alongside augmentation of CD68 and LGALS3. Thus, similarly to what was reported
for mouse SMCs and human coronary SMCs [42], in our study, HIASMCs loaded with cholesterol
may initiate conversion towards foam-type cells as indicated by their loss of SMC features and their
acquisition of macrophage-type characteristics. VSMC-derived macrophage cells not only make a
significant contribution to plaque volume and necrotic core formation but also suppress plaque stability
and promote plaque instability [43].
In addition, with the aim to explore any potential correlation between VSMC phenotypes and
patient symptomatology, we have analyzed these contractile markers in VSMCs from symptomatic
and asymptomatic plaques. Interestingly, plaques showed a similar expression pattern of PLQ vs. MIT
for MYH11 expression, i.e., reduced expression at mRNA and protein level in VSMCs coming
from symptomatic plaques compared to asymptomatic plaques. This suggests that VSMCs from
symptomatic plaques may have suffered a phenotypic modulation, while VSMCs from asymptomatic
plaques retain the contractile capacity associated with MYH11 expression [6].
Our study results contribute to a better understanding of how VSMCs affect atheroma
plaque stability processes, which may be valuable for future therapeutic approaches in carotid
atherosclerosis disease.
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